-
Signature
-
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski
-
Issuer symbol
-
APGE
-
Transactions as of
-
06 Aug 2025
-
Net transactions value
-
-$102,950
-
Form type
-
4
-
Filing time
-
08 Aug 2025, 20:00:15 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Dambkowski Carl |
Chief Medical Officer |
C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM |
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski |
08 Aug 2025 |
0001983476 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
APGE |
Common Stock |
Sale |
$102,950 |
-2,725 |
-1.1% |
$37.78 |
236,273 |
06 Aug 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: